Physician profile
Valmarie Ramos
NPI 1861724106
$12,911.63
in general payments reported to CMS, 2019-2025
62 companies · $3,186 in 2025
The $3,186 reported for 2025 was more than what 75% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $578 · 2020: $177 · 2021: $1,251 · 2022: $2,047 · 2023: $2,610 · 2024: $3,063 · 2025: $3,186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,119 · Long Term Medical Supply Or Device Loan: $2,299 · Education: $440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,119.48 |
| Long Term Medical Supply Or Device Loan | $2,299.02 |
| Education | $439.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,133.78 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $774.09 | 2019-2025 | Opdivo, Augtyro, Opdualag |
| Abbvie INC. | $735.96 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $693.17 | 2019-2025 | Enhertu, Calquence, Imfinzi |
| Janssen Biotech, INC. | $553.51 | 2019-2025 | Darzalex, Tecvayli, Imbruvica |
| Seagen INC. | $550.51 | 2019-2023 | Padcev, Tukysa, Adcetris |
| Pfizer INC. | $518.58 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $336.28 | 2021-2023 | Imbruvica |
| Celgene Corporation | $329.94 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Daiichi Sankyo INC. | $314.01 | 2019-2025 | Enhertu, Injectafer |
| Incyte Corporation | $305.07 | 2019-2025 | Jakafi, Pemazyre, Monjuvi |
| Bayer Healthcare Pharmaceuticals INC. | $294.24 | 2019-2025 | |
| Lilly USA, LLC | $289.88 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Genentech USA, INC. | $273.50 | 2019-2025 | Polivy, Venclexta, Phesgo |
| Taiho Oncology, INC. | $262.65 | 2019-2025 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $259.07 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Aveo Pharmaceuticals, INC. | $249.75 | 2023-2025 | Fotivda |
| Astellas Pharma US INC | $242.23 | 2019-2025 | Padcev, Vyloy, Xtandi |
| Eisai INC. | $237.22 | 2021-2025 | |
| Gilead Sciences, INC. | $219.45 | 2019-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $193.87 | 2023-2025 | Zejula, Jemperli, Ojjaara |
| Pharmacosmos Therapeutics INC. | $174.12 | 2023-2025 | Monoferric |
| Genmab U.S., INC. | $116.49 | 2023-2024 | Tivdak, Epkinly |
| Takeda Pharmaceuticals U.S.A., INC. | $115.18 | 2021-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Mirati Therapeutics, INC. | $110.53 | 2023-2024 | Krazati |
| Adc Therapeutics America, INC. | $101.14 | 2023-2025 | |
| Array Biopharma INC | $96.76 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Amgen INC. | $96.52 | 2019-2023 | Xgeva, Vectibix |
| Sumitomo Pharma America, INC. | $93.87 | 2023-2024 | Orgovyx |
| Tempus Ai, INC | $91.44 | 2024-2025 | Xt Cdx |
| Geron Corporation | $84.34 | 2025 | Rytelo |
| Beigene USA, INC. | $78.90 | 2022-2023 | Brukinsa |
| Foundation Medicine, INC. | $74.88 | 2019-2023 | Foundationone Cdx, Foundationone Liquid Cdx |
| Myovant Sciences INC. | $69.22 | 2021-2022 | |
| Morphosys, US INC. | $64.73 | 2022-2023 | Monjuvi |
| Puma Biotechnology, INC. | $62.02 | 2020-2025 | |
| Dendreon Pharmaceuticals LLC | $57.49 | 2021-2025 | Provenge |
| Beone Medicines USA, INC. | $51.66 | 2025 | Tevimbra, Brukinsa |
| Regeneron Healthcare Solutions, INC. | $49.76 | 2019-2022 | |
| Genzyme Corporation | $48.69 | 2021-2025 | |
| Exelixis INC. | $43.96 | 2019-2023 | Cabometyx |
| Emd Serono, INC. | $43.26 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $35.47 | 2024-2025 | Ultomiris |
| Servier Pharmaceuticals LLC | $35.20 | 2025 | |
| Agios Pharmaceuticals, INC. | $31.90 | 2025 | Pyrukynd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.08 | 2022 | |
| Sobi, INC | $27.47 | 2022-2025 | |
| Emmaus Medical, INC. | $27.04 | 2022 | |
| Immunocore Limited | $25.88 | 2025 | Kimmtrak |
| Menarini Silicon Biosystems, INC. | $22.00 | 2025 | |
| Stemline Therapeutics INC. | $21.31 | 2024 | Orserdu |
| Karyopharm Therapeutics INC. | $17.53 | 2025 | Xpovio |
| Kite Pharma, INC. | $17.13 | 2023 | Yescarta |
| Acrotech Biopharma INC. | $16.69 | 2024 | Beleodaq |
| Ge Healthcare | $16.40 | 2022 | |
| Pharmaessentia USA Corporation | $16.26 | 2024 | Besremi |
| Recordati_rare_diseases_inc. | $15.93 | 2024 | Sylvant |
| Blueprint Medicines Corporation | $14.50 | 2023 | Ayvakit |
| Jazz Pharmaceuticals INC. | $14.48 | 2019 | |
| Tesaro, INC. | $13.91 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $12.57 | 2022 | |
| Rigel Pharmaceuticals, INC. | $9.16 | 2024 | Tavalisse, Rezlidhia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Valmarie Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.